AzTrials
AzTrials

GoutPhase 2NCT05499312

An Innovative Chinese Herbal Formula for the Treatment of Gout

A Phase 2 study testing HKIIM-KU formula in people with Gout, run by Chinese University of Hong Kong at 1 site in Hong Kong.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Gout is a chronic disease of deposition of monosodium urate crystals, which form in the presence of increased urate concentrations. Gout is closely related to hyperuricaemia. Urate deposits in the joint, causing joint swelling, pain, movement disorders, affecting a significant portion of the population worldwide… Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Gout
What is being tested?
HKIIM-KU formula
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
80 participants
Where
1 siteHong Kong
Study dates
11 Oct 2022to 27 Aug 2024
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient meeting the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2015 gout classification criteria (met sufficient criterion* or total score ≥8) ;
  • History of >=1 self-reported flare of gouty arthritis within 12 months prior to randomization;
  • Agree to undergo blood test and willing to complete questionnaires and take medications as scheduled; and
  • Agree to participate in the study and provide written informed consent. (for those illiterate subjects, their family member can sign the consent form upon subject's agreement) Note: * Sufficient criterion = Presence of MSU crystals in a symptomatic joint or bursa (i.e., in synovial fluid) or tophus

Who cannot join

  • Liver-kidney yin deficiency pattern according to Chinese medicine theory;
  • Use of urate-lowering drugs within 2 weeks prior to screening;
  • Present of tophi or known history of kidney stones.
  • Known use of oral/injectable corticosteroids or other Chinese herbal medicine for treating gout within 1 month prior to screening;
  • Ongoing acute gout arthritis flare at screening or within 2 weeks prior to screening;
  • History of >4 flares overall in the 12 months prior to screening.
Show all 15Show fewer
  • Polyarticular gouty arthritis involving more than 4 joints;
  • Severe deformity, stiffness and labor loss of patients with advanced arthritis;
  • Known rheumatoid arthritis, evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis;
  • Known history of any serious diseases such as severe kidney and liver impairments, autoimmune disease, thyroid disease, Hodgkin's disease, lymphoma, severe mental disorders and leukemia
  • Known presence or suspicion of acute infectious disease;
  • Known history of malignancy within the past 5 years;
  • Known allergic to the drug used in this study;
  • Documented pregnant or lactation;
  • Subjects participating in other clinical studies at the same time.

Trial locations and contacts

1 site in 1 country.

Hong Kong1 site
  • The Chinese University of Hong Kong

    Shatin

Other trials in Hong Kong

About this study

Official title: Efficacy and Safety of an Innovative Chinese Herbal Formula for the Treatment of Gout: A Double-blind, Randomized, Placebo-Controlled Trial

Gout is a chronic disease of deposition of monosodium urate crystals, which form in the presence of increased urate concentrations. Gout is closely related to hyperuricaemia. Urate deposits in the joint, causing joint swelling, pain, movement disorders, affecting a significant portion of the population worldwide annually.

The underlying pathophysiology of gout is multifactorial, complex, and poorly understood. Thus, gout remains one of the major therapeutic challenges. Currently, western medicine treatment of gout flare includes colchicine, NSAIDs and glucocorticoids. These drugs act as analgesics, anti-inflammatory and uric acid lowering drugs. Besides, management of gout and prevention of acute flares of gout make a crucial part in gout management. To obtain uricemia target, urate lowering treatment (ULT) has been widely used in conventional management of gout. Allopurinol, probenecid and febuxostat are some of the examples of ULT. Although researchers have carried out various studies on this disease, there are severe side effects for patients with gout. Therefore, it is necessary to explore new treatments for gout with good efficacy and less side effects.

Chinese medicine (CM) is nowadays widely used for managing gout in China and other East Asian countries. Our principal Investigator (Prof. Zhi-xiu Lin), a highly experienced Registered Chinese Medicine Practitioner working at the School of Chinese Medicine, The Chinese University of Hong Kong, has been using a herbal formula (HKIIM-KU formula) to treat patients with gout in Hong Kong for many years. This formula has been observed to be effective in relieving and preventing gout and its related clinical manifestations. Hence, a double-blind, randomized, placebo-controlled, multicenter clinical trial will be employed in this study, and it would be able to provide robust clinical evidence on the efficacy and safety of HKIIM-KU formula for gout.

Read the detailed description

Gout is a chronic disease of deposition of monosodium urate crystals, which form in the presence of increased urate concentrations. Gout is closely related to hyperuricaemia. Urate deposits in the joint, causing joint swelling, pain, movement disorders. Gout affects a significant portion of the population worldwide annually. According to a recent meta-analysis, the prevalence of gout world-wide is 0.6%, while there was marked statistical heterogeneity geographically resulting of a prevalence ranging from <1% to 6.8%. The frequent attack of gout not only seriously affect the life of patients, but also lead to disability.

There are a few disease states of gout including asymptomatic hyperuricaemia, acute gouty arthritis, intercritical period, and chronic gouty arthritis. Acute flare of gout is characterized by inflamed joint arthritis which peaks within hours with signs of inflammation including redness, hotness, tenderness, swelling and loss of function. The acute attack usually resolves in 2 weeks and the patient enter into a remission phase called intercritical period. There are usually no symptoms during this period, however, proper treatment for hyperuricaemia is needed to prevent further acute attack of gout. Untreated gout or hyperuricaemia will progress into destruction of joints with formation of tophi which are accumulated monosodium urate (MSU) crystals. Joint destruction and deformity are the untreated results of gout, leading to great distress and disability.

The underlying pathophysiology of gout is multifactorial, complex, and poorly understood. It has been found that environment, genetics, immunity, diet, internal environment, trauma and stimulation are involved in the pathogenesis in various degrees. Thus, gout remains one of the major therapeutic challenges. Currently, western medicine treatment of gout flare includes colchicine, NSAIDs and glucocorticoids. These drugs act as analgesics, anti-inflammatory and uric acid lowering drugs. The mechanism of these drugs is to reduce joint inflammation, pain and uric acid level. Besides, management of gout and prevention of acute flares of gout make a crucial part in gout management. To obtain uricemia target, urate lowering treatment (ULT) has been widely used in conventional management of gout. Allopurinol, probenecid and febuxostat are some of the examples of ULT. Although researchers have carried out various studies on this disease, there are severe side effects for patients with gout. For example, Benzbromarone may cause severe renal damage. Moreover, various studies have found a strong association between human leukocyte antigen-B*58:01 (HLA-B*58:01) and allopurinol-induced severe cutaneous adverse reactions especially in Han Chinese. With such genetic predisposition, patients may develop toxic epidermal necrolysis, Steven Johnson syndrome and other life-threatening immune-mediated severe cutaneous adverse reactions with allopurinol use. It is reported that the carrier rate of the HLA-B*58:01 allele was 14% in Han Chinese in Hong Kong. Therefore, it is necessary to explore new treatments for gout with good efficacy and less side effects.

Chinese medicine (CM) is nowadays widely used for managing gout in China and other East Asian countries. In Traditional Chinese medicine (TCM), gout is classified as Bi pattern usually due to Qi stagnation in the meridians and collaterals. Among them, Zhu Liangchun Gout Decoction is one of the most commonly used formulae. Our principal Investigator (Prof. Zhi-xiu Lin), a highly experienced Registered Chinese Medicine Practitioner working at the School of Chinese Medicine, The Chinese University of Hong Kong, has been using a herbal formula (HKIIM-KU formula) to treat patients with gout in Hong Kong for many years. The formula was based on Zhu Liangchun Gout Decoction and has been modified to suit gout patients in Hong Kong. This formula has been observed to be effective in relieving and preventing gout and its related clinical manifestations. Hence, a double-blind, randomized, placebo-controlled, multicenter clinical trial will be employed in this study, and it would be able to provide robust clinical evidence on the efficacy and safety of HKIIM-KU formula for gout.

Conditions
Gout
Being tested
HKIIM-KU formula, Placebo
Medical subject headings
Gout

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • HKIIM-KU formulaDrug

    Also called HKIIM-KU

    Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.

  • PlaceboDrug

    Subjects will receive placebo granules (16.9g twice daily) for 8 weeks.

Study groups in NCT05499312
Study groupRoleWhat they receive
HKIIM-KU formulaExperimentalSubjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.
Receives: Drug: HKIIM-KU formula
PlaceboPlacebo comparatorSubjects will receive placebo granules (16.9g twice daily) for 8 weeks.
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Serum uric acid

    Blood sample for serum uric acid (sUA) will be collected. It is regarded as a controllable factor that contributing to gout. Evidence showed that gout flare risk increases when a patient's sUA fails to achieve target level.

    Measured: week 4

  2. Serum uric acid

    Blood sample for serum uric acid (sUA) will be collected. It is regarded as a controllable factor that contributing to gout. Evidence showed that gout flare risk increases when a patient's sUA fails to achieve target level.

    Measured: week 8

Secondary outcomes (19)
  1. Serum uric acid

    Blood sample for serum uric acid (sUA) will be collected. It is regarded as a controllable factor that contributing to gout. Evidence showed that gout flare risk increases when a patient's sUA fails to achieve target level.

    Measured: week 12

  2. Pain Visual Analogue Scale

    Pain VAS is validated for assessing chronic gout. A 0-10 point visual analog scale is used to reflect the pain the patient had due to gout in the past week, where score of 0 and 10 representing "No pain" and "Severe pain" respectively.

    Measured: week 2

  3. Pain Visual Analogue Scale

    Pain VAS is validated for assessing chronic gout. A 0-10 point visual analog scale is used to reflect the pain the patient had due to gout in the past week, where score of 0 and 10 representing "No pain" and "Severe pain" respectively.

    Measured: week 4

  4. Pain Visual Analogue Scale

    Pain VAS is validated for assessing chronic gout. A 0-10 point visual analog scale is used to reflect the pain the patient had due to gout in the past week, where score of 0 and 10 representing "No pain" and "Severe pain" respectively.

    Measured: week 8

  5. Pain Visual Analogue Scale

    Pain VAS is validated for assessing chronic gout. A 0-10 point visual analog scale is used to reflect the pain the patient had due to gout in the past week, where score of 0 and 10 representing "No pain" and "Severe pain" respectively.

    Measured: week 12

  6. Health Assessment Questionnaire Disability Index

    HAQ-DI is a validated tool for measuring physical function in patients with gout.

    Measured: week 2

  7. Health Assessment Questionnaire Disability Index

    HAQ-DI is a validated tool for measuring physical function in patients with gout.

    Measured: week 4

  8. Health Assessment Questionnaire Disability Index

    HAQ-DI is a validated tool for measuring physical function in patients with gout.

    Measured: week 8

  9. Health Assessment Questionnaire Disability Index

    HAQ-DI is a validated tool for measuring physical function in patients with gout.

    Measured: week 12

  10. Short Form-36

    Short Form-36 is a validated tool to assess health-related quality of life in patients with gout. It has been proven to be responsive to change in gout especially its physical component summary.

    Measured: week 2

  11. Short Form-36

    Short Form-36 is a validated tool to assess health-related quality of life in patients with gout. It has been proven to be responsive to change in gout especially its physical component summary.

    Measured: week 4

  12. Short Form-36

    Short Form-36 is a validated tool to assess health-related quality of life in patients with gout. It has been proven to be responsive to change in gout especially its physical component summary.

    Measured: week 8

  13. Short Form-36

    Short Form-36 is a validated tool to assess health-related quality of life in patients with gout. It has been proven to be responsive to change in gout especially its physical component summary.

    Measured: week 12

  14. No. of patients with new flare

    Number of patients with at least one new gout flare after baseline

    Measured: Up to week 12

  15. Time to first new flare

    Time to the first new gout flare

    Measured: Up to week 12

  16. Number of patients using rescue medication

    Number of patients using rescue medication (i.e. paracetamol) after baseline

    Measured: Up to week 12

  17. Time to first use of rescue medication

    Time to first use of rescue medication after baseline

    Measured: Up to week 12

  18. Adverse events

    Adverse events related to study treatment will be recorded.

    Measured: Up to week 12

  19. Clinical pattern/syndrome according to Chinese medicine theory

    Subjects will be assessed by Registered Chinese Medicine Practitioners (RCMPs) under Chinese medicine theory in this trial. A form will be used to record the clinical pattern/syndrome on each visit by the RCMP according to Chinese medicine theory.

    Measured: Up to week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Aug 2022
  2. Study start11 Oct 2022
  3. Primary completion27 Aug 2024
  4. Study completion27 Aug 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05499312
Sponsor's protocol ID
Gout Study
Status last verified
Jul 2026
First submitted
10 Aug 2022
Last updated
27 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing HKIIM-KU formula in people with Gout, run by Chinese University of Hong Kong at 1 site in Hong Kong.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Serum uric acid (time frame: week 4). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in